Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $728.1 million.

  • Myriad Genetics' Liabilities and Shareholders Equity fell 3266.44% to $728.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 2225.21%. This contributed to the annual value of $1.0 billion for FY2024, which is 1037.07% down from last year.
  • Latest data reveals that Myriad Genetics reported Liabilities and Shareholders Equity of $728.1 million as of Q3 2025, which was down 3266.44% from $677.3 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Liabilities and Shareholders Equity peaked at $1.4 billion during Q2 2021, and registered a low of $677.3 million during Q2 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $1.2 billion (2023), whereas its average is $1.1 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 190.05% in 2023, then crashed by 3758.18% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then decreased by 9.24% to $1.2 billion in 2022, then dropped by 4.35% to $1.1 billion in 2023, then fell by 10.37% to $1.0 billion in 2024, then decreased by 29.15% to $728.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $728.1 million in Q3 2025, compared to $677.3 million in Q2 2025 and $1.0 billion in Q1 2025.